SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-23-013741
Filing Date
2023-04-28
Accepted
2023-04-28 07:02:27
Documents
14

Document Format Files

Seq Description Document Type Size
1 DEFA14A cccc-20230427.htm   iXBRL DEFA14A 14005
5 cccc-20230427_g1.jpg GRAPHIC 81874
6 cccc-20230427_g2.jpg GRAPHIC 71834
  Complete submission text file 0001628280-23-013741.txt   545373

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20230427.xsd EX-101.SCH 1460
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20230427_lab.xml EX-101.LAB 1821
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20230427_pre.xml EX-101.PRE 591
8 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20230427_htm.xml XML 2524
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

IRS No.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39567 | Film No.: 23860085
SIC: 2836 Biological Products, (No Diagnostic Substances)